SR One is the corporate venture capital arm of GlaxoSmithKline.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantlyimpact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 17, 2022
Rezo Therapeutics
|
Series A | $78M | Biotechnology | Yes |
Sep 12, 2022
Nimbus Therapeutics
|
Series Unknown | $125M | Biotechnology | — |
Oct 3, 2019
Arcellx
|
Series B | $85M | Biopharma | — |
Jun 5, 2018
Nimbus Therapeutics
|
Series C | $65M | Biotechnology | Yes |
Mar 19, 2015
Nimbus Therapeutics
|
Series B | $43M | Biotechnology | — |